Trial Profile
A Phase I/II, Randomized, Open-Label Study of the Safety and Pharmacokinetics of Indinavir + Ritonavir Therapy in HIV-Infected Subjects Failing Amprenavir, Nelfinavir, Saquinavir, or Nelfinavir/Saquinavir Combination Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 May 2012
Price :
$35
*
At a glance
- Drugs Indinavir (Primary) ; Ritonavir (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications HIV infections
- Focus Adverse reactions; Pharmacokinetics
- 21 May 2012 Planned patient number is 50 according to ClinicalTrials.gov.
- 04 Apr 2012 New trial record